MCL1 and melanoma: For example, in melanoma, miR-32 replacement therapy as a single agent has been demonstrated to suppress the growth of melanoma tumors in preclinical models via targeting myeloid cell leukemia 1 (MCL-1) and to exhibit synergistic effects with vemurafenib.30